Genetic disruption of cutaneous de novo glucocorticoid synthesis: a CRISPR-Cas9 CYP11B1-knockout human epidermal model

CRISPR-Cas9 CYP11B1 knockout in human keratinocytes blocks de novo glucocorticoid synthesis, with two clones showing no detectable CYP11B1 protein despite preserved UVB-inducible transcript signals.

• Why it matters: Cutaneous glucocorticoids help maintain immune homeostasis and mediate environmental stress responses, but human keratinocyte pathway disruption has been limited to non-discriminatory drugs or mouse genetics.
• What they did: The authors generated two independent CYP11B1-null clones in a human epidermal model—one with a 28 bp start-codon deletion and one with a multi-exon deletion—and built stratified 3D epidermis to test differentiation and UVB responsiveness.
• The result: Knockout tissues reconstituted stratified 3D epidermal models like wild type, while wild-type showed increased CYP11B1 transcript and immunofluorescence; the knockout clones retained UVB-inducible transcripts but lacked CYP11B1 protein, enabling tissue-level study of keratinocyte-derived GC roles.

AI summary of the abstract · may contain errors · not medical advice · read the paper.